piracetam has been researched along with Multiple Sclerosis in 11 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The literature provides contrasting results on the efficacy of levetiracetam (LEV) in multiple sclerosis (MS) patients with cerebellar signs." | 9.34 | Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter double-blind, placebo-controlled, crossover study. ( Bergamaschi, R; de Sire, A; Gasperini, C; Messmer Uccelli, M; Mueller, M; Patti, F; Restivo, DA; Solaro, C; Stabile, MR, 2020) |
| "The aim of this study was to evaluate the activity measured by kinematic analysis, tolerability and efficacy of levetiracetam (LEV) in multiple sclerosis (MS) patients affected by cerebellar symptoms, in a randomized single-blind, placebo-controlled cross-over study." | 9.13 | Activity, tolerability and efficacy of levetiracetam on cerebellar symptoms in multiple sclerosis patients: a pilot kinematic study. ( Abuarqub, S; Brichetto, G; Capello, E; Sanguineti, V; Solaro, C, 2008) |
| "Levetiracetam is an anticonvulsant which is assumed to act by modulating neurotransmitter release via binding to the vesicle protein SV2A." | 6.77 | A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis. ( Falah, M; Holbech, JV; Madsen, C; Sindrup, SH, 2012) |
| "Central neuropathic pain (CNP) is a prevalent and distressing symptom in patients with multiple sclerosis (MS)." | 6.74 | Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. ( Bernardi, G; Buttari, F; Castelli, M; Centonze, D; Codecà, C; Fiore, S; Mataluni, G; Musella, A; Rossi, S, 2009) |
| "The literature provides contrasting results on the efficacy of levetiracetam (LEV) in multiple sclerosis (MS) patients with cerebellar signs." | 5.34 | Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter double-blind, placebo-controlled, crossover study. ( Bergamaschi, R; de Sire, A; Gasperini, C; Messmer Uccelli, M; Mueller, M; Patti, F; Restivo, DA; Solaro, C; Stabile, MR, 2020) |
| "Levetiracetam was effective for reducing phasic spasticity but not tonic spasticity in this 12-patient case series." | 5.32 | Levetiracetam for phasic spasticity in multiple sclerosis. ( Frohman, E; Hawker, K; Racke, M, 2003) |
| "We studied efficacy and tolerability of the combined drug omaron (25 mg of cinnarizine and 400 mg of piracetam in one tablet) in patients with multiple sclerosis." | 5.14 | [Omaron in the complex treatment of patients with multiple sclerosis]. ( Batysheva, TT; Boĭko, AN; Kamchatnov, PR; Popova, NF; Riabukhina, OV; Zaĭtsev, KA, 2010) |
| "The aim of this study was to evaluate the activity measured by kinematic analysis, tolerability and efficacy of levetiracetam (LEV) in multiple sclerosis (MS) patients affected by cerebellar symptoms, in a randomized single-blind, placebo-controlled cross-over study." | 5.13 | Activity, tolerability and efficacy of levetiracetam on cerebellar symptoms in multiple sclerosis patients: a pilot kinematic study. ( Abuarqub, S; Brichetto, G; Capello, E; Sanguineti, V; Solaro, C, 2008) |
| "A 44-year-old white woman with primary progressive MS receiving a multidrug of PO baclofen 75 mg/d, PO piracetam 3 g/d, and IV mitoxantrone 10 mg administered once a month presented to the Multiple Sclerosis Center, University of Catania, Catania, Italy." | 3.75 | Drug rash with eosinophilia and systemic signs syndrome in a patient with multiple sclerosis. ( Caruso, A; Neri, S; Patti, F; Vecchio, R, 2009) |
| "Levetiracetam is an anticonvulsant which is assumed to act by modulating neurotransmitter release via binding to the vesicle protein SV2A." | 2.77 | A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis. ( Falah, M; Holbech, JV; Madsen, C; Sindrup, SH, 2012) |
| "Central neuropathic pain (CNP) is a prevalent and distressing symptom in patients with multiple sclerosis (MS)." | 2.74 | Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. ( Bernardi, G; Buttari, F; Castelli, M; Centonze, D; Codecà, C; Fiore, S; Mataluni, G; Musella, A; Rossi, S, 2009) |
| "Secondary paroxysmal dyskinesias (SPDs) are short, episodic, and recurrent movement disorders, classically related to multiple sclerosis (MS)." | 1.46 | Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients. ( Cárcamo-Rodríguez, C; Ciampi, E; Cruz, JP; Godoy-Santín, J; Juri, C; Uribe-San-Martín, R, 2017) |
| "Levetiracetam (LEV) is an established anticonvulsant with numerous mechanisms of action." | 1.38 | Anti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitis. ( Ellrichmann, G; Faustmann, PM; Gold, R; Haghikia, A; Thöne, J, 2012) |
| "The incidence of seizures is generally accepted to be greater in patients with multiple sclerosis (MS) than in the general population, and rarely, MS can initially present as seizure." | 1.37 | Seizures as a manifestation of multiple sclerosis. ( Kendrick-Adey, AC; Sponsler, JL, 2011) |
| "Levetiracetam was effective for reducing phasic spasticity but not tonic spasticity in this 12-patient case series." | 1.32 | Levetiracetam for phasic spasticity in multiple sclerosis. ( Frohman, E; Hawker, K; Racke, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Solaro, C | 2 |
| de Sire, A | 1 |
| Messmer Uccelli, M | 1 |
| Mueller, M | 1 |
| Bergamaschi, R | 1 |
| Gasperini, C | 1 |
| Restivo, DA | 1 |
| Stabile, MR | 1 |
| Patti, F | 2 |
| Ciampi, E | 1 |
| Uribe-San-Martín, R | 1 |
| Godoy-Santín, J | 1 |
| Cruz, JP | 1 |
| Cárcamo-Rodríguez, C | 1 |
| Juri, C | 1 |
| Rossi, S | 1 |
| Mataluni, G | 1 |
| Codecà, C | 1 |
| Fiore, S | 1 |
| Buttari, F | 1 |
| Musella, A | 1 |
| Castelli, M | 1 |
| Bernardi, G | 1 |
| Centonze, D | 1 |
| Caruso, A | 1 |
| Vecchio, R | 1 |
| Neri, S | 1 |
| Popova, NF | 1 |
| Kamchatnov, PR | 1 |
| Riabukhina, OV | 1 |
| Batysheva, TT | 1 |
| Zaĭtsev, KA | 1 |
| Boĭko, AN | 1 |
| Sponsler, JL | 1 |
| Kendrick-Adey, AC | 1 |
| Falah, M | 1 |
| Madsen, C | 1 |
| Holbech, JV | 1 |
| Sindrup, SH | 1 |
| Thöne, J | 1 |
| Ellrichmann, G | 1 |
| Faustmann, PM | 1 |
| Gold, R | 1 |
| Haghikia, A | 1 |
| Hawker, K | 1 |
| Frohman, E | 1 |
| Racke, M | 1 |
| Striano, P | 1 |
| Coppola, A | 1 |
| Vacca, G | 1 |
| Zara, F | 1 |
| Brescia Morra, V | 1 |
| Orefice, G | 1 |
| Striano, S | 1 |
| Brichetto, G | 1 |
| Capello, E | 1 |
| Abuarqub, S | 1 |
| Sanguineti, V | 1 |
5 trials available for piracetam and Multiple Sclerosis
| Article | Year |
|---|---|
Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter double-blind, placebo-controlled, crossover study.
Topics: Adult; Anticonvulsants; Cross-Over Studies; Double-Blind Method; Humans; Levetiracetam; Middle Aged; | 2020 |
Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study.
Topics: Adult; Analgesics; Anticonvulsants; Depression; Disability Evaluation; Female; Humans; Levetiracetam | 2009 |
[Omaron in the complex treatment of patients with multiple sclerosis].
Topics: Adult; Cinnarizine; Drug Combinations; Fatigue Syndrome, Chronic; Female; Humans; Male; Middle Aged; | 2010 |
A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis.
Topics: Adult; Analgesics; Anticonvulsants; Chronic Pain; Cross-Over Studies; Female; Humans; Hyperalgesia; | 2012 |
Activity, tolerability and efficacy of levetiracetam on cerebellar symptoms in multiple sclerosis patients: a pilot kinematic study.
Topics: Biomechanical Phenomena; Cerebellum; Female; Humans; Levetiracetam; Male; Multiple Sclerosis; Nootro | 2008 |
6 other studies available for piracetam and Multiple Sclerosis
| Article | Year |
|---|---|
Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
Topics: Acetazolamide; Adult; Anticonvulsants; Cerebellum; Clonazepam; Dyskinesias; Dystonia; Female; Follow | 2017 |
Drug rash with eosinophilia and systemic signs syndrome in a patient with multiple sclerosis.
Topics: Administration, Oral; Adult; Baclofen; Biopsy; Chemical and Drug Induced Liver Injury; Cholestasis; | 2009 |
Seizures as a manifestation of multiple sclerosis.
Topics: Adult; Anticonvulsants; Brain; Electroencephalography; Epilepsy, Tonic-Clonic; Female; Humans; Levet | 2011 |
Anti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Disease Models, Animal; Disease P | 2012 |
Levetiracetam for phasic spasticity in multiple sclerosis.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middl | 2003 |
Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study.
Topics: Activities of Daily Living; Adult; Anticonvulsants; Cerebellar Neoplasms; Disability Evaluation; Fem | 2006 |